Literature DB >> 23913731

Adipocyte size is associated with NAFLD independent of obesity, fat distribution, and PNPLA3 genotype.

Elina M Petäjä1, Ksenia Sevastianova, Antti Hakkarainen, Marju Orho-Melander, Nina Lundbom, Hannele Yki-Järvinen.   

Abstract

OBJECTIVE: Adipocyte hypertrophy has been suggested to be causally linked with inflammation and systemic insulin resistance. The aim of the study was to determine whether increased adipocyte size is associated with increased liver fat content due to nonalcoholic fatty liver disease (NAFLD) in humans independent of obesity, fat distribution and genetic variation in the patatin-like phospholipase domain-containing 3 gene (PNPLA3; adiponutrin) at rs738409. DESIGN AND METHODS: One hundred nineteen non-diabetic subjects in a cross-sectional study with a median age of 39 years, mean ± SD BMI of 30.0 ± 5.7 kg m(-2) were studied. Abdominal subcutaneous (SC) adipocyte size, liver fat [proton magnetic resonance spectroscopy ((1) H-MRS)], intra-abdominal (IA), and abdominal SC adipose tissue volumes [magnetic resonance imaging (MRI)] and the PNPLA3 genotype at rs738409 were determined. Univariate and multiple linear regression analysis were used to identify independent predictors of liver fat content.
RESULTS: In multiple linear regression analysis, age, gender, BMI, the IA/SC ratio, and PNPLA3 genotype explained 42% of variation in liver fat content. Addition of adipocyte size (P < 0.0001) to the model increased the percent of explanation to 53%. Thus, 21% of known variation in liver fat could be explained by adipocyte size alone.
CONCLUSIONS: Increased adipocyte size highly significantly contributes to liver fat accumulation independent of other causes.
Copyright © 2012 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23913731     DOI: 10.1002/oby.20114

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  8 in total

1.  What Is the Role of the New Index Relative Fat Mass (RFM) in the Assessment of Nonalcoholic Fatty Liver Disease (NAFLD)?

Authors:  Mariana V Machado; Sara Policarpo; J Coutinho; Sofia Carvalhana; Jorge Leitão; Armando Carvalho; Ana P Silva; Francisco Velasco; Isabel Medeiros; Ana Catarina Alves; Mafalda Bourbon; Helena Cortez-Pinto
Journal:  Obes Surg       Date:  2020-02       Impact factor: 4.129

Review 2.  Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease.

Authors:  Frank T Spradley; Jillian A Smith; Barbara T Alexander; Christopher D Anderson
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-03-06       Impact factor: 4.310

Review 3.  Assessing Obesity-Related Adipose Tissue Disease (OrAD) to Improve Precision Medicine for Patients Living With Obesity.

Authors:  Yair Pincu; Uri Yoel; Yulia Haim; Nataly Makarenkov; Nitzan Maixner; Ruthy Shaco-Levy; Nava Bashan; Dror Dicker; Assaf Rudich
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-29       Impact factor: 6.055

4.  ASK1 (MAP3K5) is transcriptionally upregulated by E2F1 in adipose tissue in obesity, molecularly defining a human dys-metabolic obese phenotype.

Authors:  Yulia Haim; Matthias Blüher; Daniel Konrad; Nir Goldstein; Nora Klöting; Ilana Harman-Boehm; Boris Kirshtein; Doron Ginsberg; Tanya Tarnovscki; Yftach Gepner; Iris Shai; Assaf Rudich
Journal:  Mol Metab       Date:  2017-05-06       Impact factor: 7.422

5.  Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease.

Authors:  M V Machado; G A Michelotti; M L Jewell; T A Pereira; G Xie; R T Premont; A M Diehl
Journal:  Cell Death Dis       Date:  2016-02-18       Impact factor: 8.469

6.  Cytometric analysis of adipose tissue reveals increments of adipocyte progenitor cells after weight loss induced by bariatric surgery.

Authors:  Jesús García-Rubio; Josefa León; Anaïs Redruello-Romero; Esther Pavón; Antonio Cozar; Francisco Tamayo; Mercedes Caba-Molina; Javier Salmerón; Ángel Carazo
Journal:  Sci Rep       Date:  2018-10-12       Impact factor: 4.379

Review 7.  Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction.

Authors:  Harold Bays
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

8.  Fat Cell Size: Measurement Methods, Pathophysiological Origins, and Relationships With Metabolic Dysregulations.

Authors:  Run Zhou Ye; Gabriel Richard; Nicolas Gévry; André Tchernof; André C Carpentier
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.